Effect of interleukin-2 on diabetes in the BB/Wor rat.
Young diabetes prone BB/Wor rats were treated for 4-7 weeks with low dose (1,000 units/week) or high dose (75,000 units/week) recombinant human interleukin-2 (IL-2) and observed through 150 days of age for the development of spontaneous diabetes mellitus. Comparing treated rats with controls, it was found that IL-2 did not affect the cumulative incidence of diabetes, the age at onset of the disease, or peripheral lymphocyte subset numbers. High dose IL-2 administered to diabetes resistant BB/Wor rats also failed to induce the disease.